$7.01
3.04% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US00289Y1073
Symbol
ABEO

Abeona Therapeutics, Inc. Stock price

$7.01
+0.48 7.35% 1M
+1.68 31.52% 6M
+1.44 25.85% YTD
+1.27 22.13% 1Y
+2.50 55.43% 3Y
-52.99 88.32% 5Y
-102.99 93.63% 10Y
-4,555.49 99.85% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.22 3.04%
ISIN
US00289Y1073
Symbol
ABEO
Industry

Key metrics

Basic
Market capitalization
$370.7m
Enterprise Value
$164.8m
Net debt
positive
Cash
$225.5m
Shares outstanding
51.3m
Valuation (TTM | estimate)
P/E
8.5 | negative
P/S
926.9 | 13.7
EV/Sales
412.0 | 6.1
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
40.4%
Return on Equity
-144.8%
ROCE
-35.2%
ROIC
2,653.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$400.0k | $27.1m
EBITDA
$-71.5m | -
EBIT
$-74.5m | $-58.7m
Net Income
$57.2m | $-5.0m
Free Cash Flow
$-71.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-31.6% | -
EBIT
-31.4% | 8.6%
Net Income
208.8% | 92.1%
Free Cash Flow
-63.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-17,863.8% | -
EBIT
-18,634.0%
Net
14,310.5% | -18.5%
Free Cash Flow
-17,822.8%
More
EPS
$0.9
FCF per Share
$-1.4
Short interest
17.6%
Employees
136
Rev per Employee
$0.0
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.40 0.40
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
59% 59%
10,255%
- Research and Development Expense 34 34
9% 9%
8,455%
-71 -71
32% 32%
-17,865%
- Depreciation and Amortization 3.08 3.08
27% 27%
770%
EBIT (Operating Income) EBIT -75 -75
31% 31%
-18,634%
Net Profit 57 57
209% 209%
14,310%

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Brian Kevany - Senior VP, CTO & CSO Gregory Gin - Vice President of Investor Relations & Corporate Communications Joseph Walter Vazzano - Chief Financial Officer Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Vishwas Seshadri - Presid...
Positive
Seeking Alpha
10 days ago
The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform and ABO-503 gene therapy offer differentiated potential in rare eye disorders, with key catalysts in 2025-2026. ABEO expansion opportunities exist via licensing deals, notably with Beacon Therapeutic...
Neutral
GlobeNewsWire
11 days ago
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today